Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-short-course rifapentine and isoniazid for TB prevention in HIV
NCT01404312Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2012
- Primary completion
- Nov 2017
- Countries
- 10
01
Overview
A Phase 3 trial of rifapentine in Tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started May 2012; status: completed.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01404312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01404312.